Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Next Previous
Search
Trial Profile

RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinopathy of prematurity
  • Focus Registrational; Therapeutic Use
  • Acronyms RainbowExt
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharma KK; Novartis Pharmaceuticals

    • Most Recent Events

    • 13 Dec 2022 Status changed from active, no longer recruiting to completed.
    • 23 May 2022 This trial has been completed in Austria (Global end date: 21 Apr 2022).
    • 15 May 2022 This trial has been completed in Belgium and Croatia (Date of the global end of the trial : 21-Apr-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top